Go back

Qsauri
"D"

data exclusivity
Guideline or reference source
EMA Glossary of terms
Definition
The period of eight years from the initial authorisation of a medicine during which the marketing-authorisation holder benefits from the exclusive rights to the results of preclinical tests and clinical trials on the medicine. After this period, the marketing-authorisation holder is obliged to release this information to companies wishing to develop generic versions of the medicine  

Send comments to info@celegence.com Please read disclaimer before using Qsauri.